Daccò L, Barbagallo M, Carbognati A, Girasole G
Clin Ther. 1986;8(4):450-8.
Forty patients, aged 51 to 79 years, with nocturia due to bladder instability, resorption of postural edema, or senile decay, were treated with rociverine or flavoxate to test the possibility of reducing or eliminating nocturnal voidings. After a two-day observation period, each patient received either 20 mg of rociverine or 200 mg of flavoxate in a single dose at 8 PM. The following were assessed before the trial and after 14 and 28 days of treatment: number of night voidings, interval between drug administration and first voiding, volume of first voiding, volume of urine voided during the night, volume of morning urine, and total volume of urine passed between 8 PM and 8 AM. Routine laboratory tests performed before and after the trial showed both drugs to be well tolerated. The results of the trial show that rociverine reduced the number of night voidings significantly more (P less than 0.05) than did flavoxate.
40名年龄在51至79岁之间，因膀胱不稳定、体位性水肿吸收或衰老而出现夜尿症的患者，接受了罗西维林或黄酮哌酯治疗，以测试减少或消除夜间排尿的可能性。经过为期两天的观察期后，每位患者于晚上8点单次服用20毫克罗西维林或200毫克黄酮哌酯。在试验前以及治疗14天和28天后评估以下指标：夜间排尿次数、给药至首次排尿的间隔时间、首次排尿量、夜间排尿量、晨尿体积以及晚上8点至早上8点期间的总尿量。试验前后进行的常规实验室检查表明，两种药物的耐受性均良好。试验结果显示，罗西维林比黄酮哌酯更显著地减少了夜间排尿次数（P小于0.05）。
